Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

[1] Afkarian M(2013)Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 302-308

[2] Sachs MC(2002)Molecular understanding of hyperglycemia’s adverse effects for diabetic complications JAMA 288 2579-2588

[3] Kestenbaum B(2007)Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes Nat Clin Pract Endocrinol Metab 3 46-56

[4] Hirsch IB(2003)Circulating endothelial progenitor cells, vascular function, and cardiovascular risk N Engl J Med 348 593-600

[5] Tuttle KR(2009)Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease Am J Physiol Renal Physiol 296 1314-2786

[6] Himmelfarb J(2002)Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures Circulation 106 2781-116

[7] Sheetz MJ(2006)Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease Arterioscler Thromb Vasc Biol 26 112-967

[8] King GL(2017)Use of p53-silenced endothelial progenitor cells to treat ischemia in diabetic peripheral vascular disease J Am Heart Assoc. 56 960-2207

[9] Rask-Madsen C(2007)Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells Diabetes 359 2195-1609

[10] King GL(2008)Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein N Engl J Med 33 1607-1519

[1] Afkarian M(2013)Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 302-308

[2] Sachs MC(2002)Molecular understanding of hyperglycemia’s adverse effects for diabetic complications JAMA 288 2579-2588

[3] Kestenbaum B(2007)Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes Nat Clin Pract Endocrinol Metab 3 46-56

[4] Hirsch IB(2003)Circulating endothelial progenitor cells, vascular function, and cardiovascular risk N Engl J Med 348 593-600

[5] Tuttle KR(2009)Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease Am J Physiol Renal Physiol 296 1314-2786

[6] Himmelfarb J(2002)Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures Circulation 106 2781-116

[7] Sheetz MJ(2006)Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease Arterioscler Thromb Vasc Biol 26 112-967

[8] King GL(2017)Use of p53-silenced endothelial progenitor cells to treat ischemia in diabetic peripheral vascular disease J Am Heart Assoc. 56 960-2207

[9] Rask-Madsen C(2007)Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells Diabetes 359 2195-1609

[10] King GL(2008)Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein N Engl J Med 33 1607-1519